Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe
Francesco Maisano, Olaf Franzen, Stephan Baldus, Ulrich Schäfer, Jörg Hausleiter, Christian Butter, Gian Paolo Ussia, Horst Sievert, Gert Richardt, Julian D Widder, Tiziano Moccetti, Wolfgang Schillinger, Francesco Maisano, Olaf Franzen, Stephan Baldus, Ulrich Schäfer, Jörg Hausleiter, Christian Butter, Gian Paolo Ussia, Horst Sievert, Gert Richardt, Julian D Widder, Tiziano Moccetti, Wolfgang Schillinger
Abstract
Objectives: The purpose of this article is to report early and mid-term outcomes of the ACCESS-EU study (ACCESS-Europe A Two-Phase Observational Study of the MitraClip System in Europe), a European prospective, multicenter, nonrandomized post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).
Background: MitraClip has been increasingly performed in Europe after approval; the ACCESS-EU registry provides a snapshot of the real-world clinical demographic data and outcomes.
Methods: A total of 567 patients with significant mitral valve regurgitation (MR) underwent MitraClip therapy at 14 European sites. Mean logistic European System for Cardiac Operative Risk Evaluation at baseline was 23.0 ± 18.3; 84.9% patients were in New York Heart Association functional class III or IV, and 52.7% of patients had an ejection fraction ≤40%.
Results: The MitraClip implant rate was 99.6%. A total of 19 patients (3.4%) died within 30 days after the MitraClip procedure. The Kaplan-Meier survival at 1 year was 81.8%. Intensive care unit and hospital length of stay was 2.5 ± 6.5 days and 7.7 ± 8.2 days, respectively. Single leaflet device attachment was reported in 27 patients (4.8%). There were no MitraClip device embolizations. Thirty-six subjects (6.3%) required mitral valve surgery within 12 months after the MitraClip implant procedure. There was improvement in the severity of MR at 12 months, compared with baseline (p < 0.0001), with 78.9% of patients free from MR, severity of >2+ at 12 months. At 12 months, 71.4% of patients had New York Heart Association functional class II or class I. Six-min-walk-test improved 59.5 ± 112.4 m, and Minnesota-living-with-heart-failure score improved 13.5 ± 20.5 points.
Conclusions: In the real-world, post-approval experience in Europe, patients undergoing the MitraClip therapy are high-risk, elderly patients, mainly affected by functional MR. In this patient population, the MitraClip procedure is effective with low rates of hospital mortality and adverse events.
Keywords: 6-min walk test; 6MWT; CI; DMR; EF; EuroSCORE; European System for Cardiac Operative Risk Evaluation; FMR; MLHFQ; MR; Minnesota Living with Heart Failure quality of life questionnaire; MitraClip; NYHA; New York Heart Association; SLDA; confidence interval; degenerative mitral valve regurgitation; double orifice repair; ejection fraction; functional mitral valve regurgitation; mitral regurgitation; mitral valve; mitral valve regurgitation; percutaneous mitral valve repair; single leaflet device attachment.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed